货号:A150093
同义名:
依普拉封;异普黄酮
/ 7-Isopropoxyisoflavone; Osteofix
Ipriflavone 是一种合成异黄酮衍生物,用于骨质疏松及骨代谢机制研究。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Ipriflavone is used to inhibit bone resorption. |
| Concentration | Treated Time | Description | References | |
| Bovine chondrocytes | 10 μM | 3, 6, 9 days | To investigate the effects of ipriflavone on GAG loss and HA molecular weight in bovine cartilage explants under IL-1β stimulation. Results showed that ipriflavone reduced GAG losses and increased the molecular weight of HA. | Int J Mol Sci. 2023 Aug 4;24(15):12422 |
| Fibroblast-like synoviocytes (FLS) | 2 μM, 10 μM | 24 hours | Ipriflavone increased HA accumulation and suppressed MMP1 and MMP3 expression in TNF-α-stimulated FLS. | Int J Mol Sci. 2022 Apr 7;23(8):4089 |
| Rat chondrosarcoma (RCS) cells | 1 μM, 5 μM, 10 μM, 20 μM | 24 hours | Ipriflavone significantly restored the Alcian blue staining of RCS-KIAA cells, dose-dependently increased extracellular matrix formation, and reduced HA leakage into the culture medium. | Int J Mol Sci. 2022 Apr 7;23(8):4089 |
| Primary tubular epithelial cells (PTCs) | 200 nM | Upregulated DHHC9 expression, downregulated β-catenin levels, and inhibited TGF-β1-induced fibronectin (FN) production | Arthritis Res Ther. 2019 May 2;21(1):109 | |
| Primary neurons | 5–20 μM | IP suppressed tau hyperphosphorylation via GR/PI3K/AKT/GSK3β pathway | Aging Cell. 2022 Mar;21(3):e13572 | |
| Human periodontal ligament cells (hPDLCs) | 10^-7 M | 24, 48, 72 hours | Promote proliferation and osteogenic differentiation of hPDLCs | Drug Des Devel Ther. 2018 Jan 11;12:137-148 |
| Administration | Dosage | Frequency | Description | References | ||
| Male Sprague Dawley rats | Dexamethasone-induced osteoporotic animal model | Oral gavage | 50 mg/kg | Daily administration for 8 weeks | To evaluate the therapeutic effect of Ipriflavone on dexamethasone-induced osteoporosis. Results showed that Ipriflavone significantly increased bone mineral density and bone mineral content, reduced bone resorption markers (such as TRAP and ACP), and improved bone histomorphology. | Antioxidants (Basel). 2022 Mar 6;11(3):508 |
| C57BL/6J mice | Destabilization of the medial meniscus (DMM)-induced osteoarthritis model | Oral | 200 mg/kg/day | Daily administration for 4, 6, 8, 10 weeks | To evaluate the effects of ipriflavone on DMM-induced osteoarthritis in mice. Results showed that ipriflavone significantly reduced the Mankin score, decreased KIAA1199 expression, and preserved HA stainability. | Int J Mol Sci. 2023 Aug 4;24(15):12422 |
| DBA/1 J mice | Collagen-induced arthritis (CIA) mouse model | Oral | 100 mg/kg, 200 mg/kg | Once daily for 3 weeks | Ipriflavone significantly improved the symptoms and reduced the serum concentrations of HA in CIA mice. | Int J Mol Sci. 2022 Apr 7;23(8):4089 |
| Mice | STZ-induced diabetic mice and HFD/STZ-induced diabetic mice | 20 and 40 mg/kg | IP ameliorated diabetic cognitive impairment by antagonizing GR, including tau hyperphosphorylation, synaptic impairment, and neuroinflammation | Aging Cell. 2022 Mar;21(3):e13572 | ||
| Wistar rats | Orthodontic tooth movement (OTM) model | Intragastric administration | 10 mg/kg/day | Once daily for 10 days | Promote periodontal tissue remodeling and bone formation | Drug Des Devel Ther. 2018 Jan 11;12:137-148 |
| Male mice | Unilateral ureter obstruction (UUO) or ischemia/reperfusion injury (IRI)-induced kidney fibrosis models | 0.3 mg/kg body weight/day | Continued until the experimental endpoint | Upregulated renal DHHC9 expression and alleviated UUO- or IRI-induced kidney fibrosis | Arthritis Res Ther. 2019 May 2;21(1):109 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.57mL 0.71mL 0.36mL |
17.84mL 3.57mL 1.78mL |
35.67mL 7.13mL 3.57mL |
|
| CAS号 | 35212-22-7 |
| 分子式 | C18H16O3 |
| 分子量 | 280.32 |
| SMILES Code | O=C1C(C2=CC=CC=C2)=COC3=CC(OC(C)C)=CC=C13 |
| MDL No. | MFCD00221719 |
| 别名 | 依普拉封;异普黄酮;依普瑞丰;易卜拉封;异丙黄酮 ;7-Isopropoxyisoflavone; Osteofix; TC 80; Yambolap; FL-113 |
| 运输 | 蓝冰 |
| InChI Key | SFBODOKJTYAUCM-UHFFFAOYSA-N |
| Pubchem ID | 3747 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, room temperature |
| 溶解方案 |
DMSO: 35 mg/mL(124.86 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1